Inhibitex Announces Data Presentation at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL)
ATLANTA--(BUSINESS WIRE)--Mar 31, 2011 - Inhibitex, Inc. (NASDAQ: INHX) announced today the presentation of data from its single ascending dose Phase 1a study of INX-189 in healthy volunteers. The poster presentation will be presented by various scientists from the Company at the 46th European Association for the study of the Liver in Berlin, Germany. The abstract can be viewed at the EASL website at www.easl.eu.
The following poster will be presented during the Viral Hepatitis C: Clinical (Therapy) Poster Session, today, March 31, 2011, from 9:00 am - 6:00 pm CEST.
- ID #460; Barry et al., “A STUDY OF THE SAFETY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF INX-08189, A NUCLEOTIDE POLYMERASE INHIBITOR, IN HEALTHY SUBJECTS"
The poster will be available in the INX-189 section of the Inhibitex website.
Inhibitex, Inc., a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company's pipeline includes FV-100, which is in Phase II clinical development for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of staphylococcal vaccines. For additional information about the Company, please visit www.inhibitex.com.
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.
Posted: March 2011